Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +117.81%
#2 Lisk Lisk +81.56%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +30.37%
#4 Tokenlon Tokenlon +28.92%
#5 Alchemist AI Alchemist AI +28.02%
#6 Nockchain Nockchain +25.68%
#7 earnAUSD earnAUSD +24.75%
#8 Renzo Renzo +21.89%
#9 Illuvium Illuvium +19.74%
#10 Akedo Akedo +18.38%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Classifica tra le azioni #41009
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Prezzo delle azioni
$0.00001
Ultima sincronizzazione: 2026-09-10
Capitalizzazione di mercato
$50.01K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia MultiCell Technologies, Inc. (MCET)

Categoria

Healthcare
Ricavi di MultiCell Technologies, Inc. (MCET)
Ricavi nel Aug 2015 TTM: $805.24
Secondo gli ultimi rapporti finanziari di MultiCell Technologies, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $805.24. Nel 2013, l'azienda ha registrato ricavi di $49.32 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per MultiCell Technologies, Inc. da 2013 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $805.24 1,532.68%
2014 $49.32 0.00%
2013 $49.32 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 1,567,776,303.44%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 747,766,680.05%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 276,688,970.04%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 1,955,243,721.94%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH